| Name | Other Names | Primary Prevention | Secondary Prevention | Diagnostic | Prognostic | Recurrence | Monitoring | Specimen |
|---|---|---|---|---|---|---|---|---|
| Acid phosphatase, total and prostatic | PAP | x | x | x | serum | |||
| Adrenocorticotropic hormone | ACTH | x | plasma | |||||
| Alpha fetoprotein | AFP | x | x | x | x | serum | ||
| AML1/ETO translocation | t(8;21) | x | x | x | x | blood, marrow | ||
| B-cell gene rearrangement | x | x | x | blood, marrow, tissue | ||||
| BCL-1/JH gene rearrangement | t(11;14) | x | x | x | blood, marrow, tissue | |||
| BCL-2 translocation | t(14;18) | x | x | x | x | blood, marrow, tissue | ||
| BCR/ABL gene rearrangement | Philadelphia chromosome | x | x | x | x | blood, marrow | ||
| Beta human chorionic gonadotropin | b-HCG | x | x | x | serum | |||
| Beta-2 microglobulin | x | x | serum | |||||
| Bladder tumor antigen | BTA | x | x | urine | ||||
| BRCA Analysis | BRCA1, BRCA2 | x | x | blood | ||||
| Calcitonin | x | x | x | x | serum | |||
| Cancer antigen 125 | CA 125 | x | x | serum | ||||
| Cancer antigen 15-3 | CA 15-3 | x | x | serum | ||||
| Cancer antigen 19-9 | CA 19-9 | x | x | serum | ||||
| Cancer antigen 27.29 | CA 27.29 | x | x | serum | ||||
| Carcinoembryonic antigen | CEA | x | x | x | x | serum | ||
| Cathepsin D | x | tissue | ||||||
| CBFB/MYH11 fusion protein | inv(16), t(16;16) | x | x | x | blood, marrow | |||
| CD 117, c-kit | Gleevec sensitivity | x | tissue | |||||
| CD 20 | Rituxan sensitivity | x | blood | |||||
| CD 25 | Ontak sensitivity | x | Blood, marrow, tissue | |||||
| CD 33 | Mylotarg sensitivity | x | Blood, marrow | |||||
| CD 52 | Campath sensitivity | x | Blood, marrow | |||||
| Chromosome 18q assay | 18q/RER, DCC | x | x | Blood, tissue | ||||
| Colaris | MLH1, MSH2 | x | x | Blood | ||||
| Colaris AP | APC, FAP | x | x | Blood | ||||
| Cyclin-D1 | x | x | Tissue | |||||
| E-cadherin | x | Tissue | ||||||
| Epidermal growth factor receptor | EGFR pharmDx, HER-1, Erbitux sensitivity | x | Tissue | |||||
| Estrogen/progesterone receptor | ER/PR | x | x | Tissue | ||||
| Fecal globin | InSure, FOBT | x | Stool | |||||
| FLT 3 mutation | x | Blood | ||||||
| HER-2/neu | c-erbB-2, PathVysion, Herceptin eligibility | x | x | Tissue | ||||
| 5-HIAA | 5-hydroxyindoleacetic acid | x | x | Urine | ||||
| Human papillomavius hybrid capture | HPV, ThinPrep | x | Pap smear | |||||
| IgVH mutation analysis | x | Blood, marrow | ||||||
| Immunocyt | mucin, CEA | x | x | Urine | ||||
| Kappa/lambda light chain | x | Blood, tissue | ||||||
| LAP | leukocyte alkaline phosphatase | x | x | Blood, marrow | ||||
| Lipid associated sialic acid | LASA, LSA | x | x | Serum | ||||
| Melaris | p16 | x | Blood | |||||
| MIB-1 antibody | Ki-67 antigen | x | Tissue | |||||
| Micrometastasis detection | cytokeratins | x | x | Marrow, tissue | ||||
| Microsatellite instability | MSI, BAT-26, RER+, HNPCC | x | x | x | x | Blood, tissue | ||
| MLH1, MSH2, MSH6 mutations | HNPCC mismatch repair gene | x | Blood | |||||
| Neuron specific enolase | NSE | x | Serum | |||||
| Nuclear matrix proteins | NMP 22 | x | x | x | Urine | |||
| Oncotype Dx | Breast cancer assay | x | Tissue | |||||
| p53 tumor suppressor gene | p53 | x | Tissue | |||||
| PML/RARA translocation | t(15;17) | x | x | x | Blood, marrow | |||
| PreGen-26 | MSI, BAT-26 | x | x | x | Stool | |||
| PreGen-Plus | k-ras, APC, p53 | x | x | Stool | ||||
| Prostate-specific antigen | PSA free, total, ultrasensitive, HAMA | x | x | x | x | Blood | ||
| T-cell recepter gene rearrangment | x | Blood, marrow, tissue | ||||||
| TEL/AML1 gene fusion | t(12;21) | x | x | x | Blood, marrow | |||
| Thyroglobulin | x | x | Serum | |||||
| Tumor antigen 90 immune complex | TA90-IC | x | x | x | Serum | |||
| Urokinase plasminogen activator | uPA, PAI-1 (plasminogen activitor inhibitor) | x | Tissue | |||||
| Urovysion | Vysis Urovysion | x | Urine | |||||
| ZAP-70 | x | Blood, marrow |